[ad_1]
Every year in Italy, more than 52,000 women are diagnosed with bad cancer and about 12,000 of them are suffering from metastatic cancer, which leads to a life expectancy very different from that of the majority of patients with this tumor discovered at the initial stage. There are now very effective treatments that, even if they can not lead to scarring, can make the disease chronic and therefore treat it for very long periods, allowing women with cancer metastatic bad to have more time to heal. A quantitative and qualitative point of view to be able to lead a normal life. Metastatic bad cancer is a very often incurable, but almost always chronic disease – explains Michelino De Laurentiis, director of the department of medical oncology at the National Cancer Institute. Pascale di Napoli -. This means that it is possible, by judiciously and in the right order, to use the available therapies, to obtain control of the disease and to regress it, thus allowing patients to live with the tumor for years. years.
New care at the forefront, from the onset of metastases
New therapeutic options, especially those in the first line (ie those used in the development of metastases) play an important role because of their high level of efficacy and tolerance, adds Mr. From Laurentiis. These new therapies are in the direction of chronic disease, it is a neoplasm that we can not eliminate permanently, but we can always better control, allowing the person to lead a life reasonably normal with little effect secondary. Italians living with metastatic bad cancer have recently added a new drug (ribociclib), which has recently received reimbursement from the Italian Medicines Agency as a first-line treatment in postmenopausal women with high blood pressure. advanced bad cancer locally. or metastatic positive for the hormone receptor (HR) and negative for the human epidermal growth factor receptor 2 (HER2).
<! –
"I had a bad tumor, I was preparing to die, and today I'm fine."
In the fall of 2015, Judy was ready to die
40,000 Italian women with metastatic bad cancer
Of the 40,000 Italian women with metastatic bad cancer, about 70% have positive hormone receptors – explains Lucia Del Mastro, coordinator of the Breast Unit of San Martino Hospital in Genoa – : this means that they can benefit from a hormonal type treatment. And the most important novelties for this subgroup of patients, the most numerous in terms of incidence, are represented by the introduction of cicline inhibitors, such as ribociclib: we are talking about Therapeutic options that may increase the effectiveness of cancer treatments. hormonal norms. This means having a treatment to control the disease for a much longer period than was possible with the previous options. The higher efficacy also implies low toxicity, allowing these women to live a normal life while continuing the treatment of their metastatic disease.
Disease under control for two years
The advantage of this clbad of drugs, called cyclin-type 4/6-dependent kinase inhibitors (or, more simply, cicline inhibitors), which is used primarily during the development of metastases from one to the next. hormone-sensitive bad cancer, is: able to double the effectiveness of a basic hormone therapy, allowing most patients excellent control of the disease without resorting to chemotherapy. The badociation between ribociclib and hormone therapy is more effective than any available chemotherapy – says De Laurentiis – while being better tolerated by patients: for this reason, it is possible to To obtain control of the disease by giving the patient a substantially normal life. In terms of time, the experiments showed that with a single therapeutic line based on hormone therapy and ribociclib, it is possible to have a median of free time from the progression of the disease, by about 25 months . This means that in 50% of patients, the disease will be under control (without progress) over two years. This strategy is also studied in younger, pre-menopausal women with advanced carcinoma. Until now, the combination of pi-ribociclib hormone therapy has shown high efficacy also in this subgroup of patients – concludes Del Mastro -. This means having a low-toxicity and high-efficiency therapeutic option, very important in a particular way for women in very active life, from both a family and social point of view and from work. This opportunity allows them to continue to live a normal life with a significant gain in both quantity and quality of life.
November 29, 2018 (amended 29 November 2018 | 16:19)
© RESERVED COPY
[ad_2]
Source link
